The Oncology Institute, Inc. (TOI)
NASDAQ: TOI · IEX Real-Time Price · USD
1.580
-0.260 (-14.13%)
At close: Mar 28, 2024, 4:00 PM
1.550
-0.030 (-1.90%)
After-hours: Mar 28, 2024, 5:08 PM EDT

The Oncology Institute Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Revenue
324.24252.48203187.52155.41
Revenue Growth (YoY)
28.42%24.37%8.26%20.66%-
Cost of Revenue
264.67200.39162.16150.64125.46
Gross Profit
59.5752.0940.8536.8829.94
Selling, General & Admin
113.85119.6983.3741.929.64
Other Operating Expenses
22.7414.363.343.182.94
Operating Expenses
136.59134.0486.7145.0832.59
Operating Income
-77.02-81.95-45.86-8.2-2.64
Interest Expense / Income
6.784.080.320.350
Other Expense / Income
-15.88-85.86-34.886.27-0.01
Pretax Income
-67.91-0.18-11.3-14.82-2.64
Income Tax
-0.04-0.24-0.67-0.491.38
Net Income
-67.880.07-10.63-14.32-4.02
Shares Outstanding (Basic)
7473665910
Shares Outstanding (Diluted)
7481665910
Shares Change
-8.51%21.70%12.03%491.18%-
EPS (Basic)
-0.92--0.16-0.24-402.14
EPS (Diluted)
-0.92-0.21-0.16-0.24-402.14
Free Cash Flow
-40.88-67.29-35.53-0.692.41
Free Cash Flow Per Share
-0.55-0.92-0.54-0.010.24
Gross Margin
18.37%20.63%20.12%19.67%19.27%
Operating Margin
-23.75%-32.46%-22.59%-4.37%-1.70%
Profit Margin
-20.93%0.03%-5.24%-7.64%-2.59%
Free Cash Flow Margin
-12.61%-26.65%-17.50%-0.37%1.55%
EBITDA
-55.268.32-7.64-11.290.31
EBITDA Margin
-17.04%3.29%-3.76%-6.02%0.20%
Depreciation & Amortization
5.874.413.343.182.94
EBIT
-61.143.91-10.98-14.47-2.63
EBIT Margin
-18.86%1.55%-5.41%-7.72%-1.70%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).